Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 2/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 6/20 | 0.42 |
| ▸ | MMP2 | P08253 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 4/20 | 0.40 |
| ▸ | MMP8 | P22894 | 4/20 | 0.40 |
| ▸ | MMP13 | P45452 | 4/20 | 0.40 |
| ▸ | MMP14 | P50281 | 4/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100719 | 1.00 | CACNA1H (0.43) | CACNA1HCACNA1BMMP9MMP2CA1 | |
| SCHEMBL1100926 | 0.90 | PGR (0.44) | CACNA1HCACNA1BMMP9MMP2CYP19A1 | |
| SCHEMBL1108519 | 0.90 | PGR (0.44) | CACNA1HCACNA1BMMP9MMP2CYP19A1 | |
| SCHEMBL1099297 | 0.90 | CA1 (0.44) | MMP9MMP2CA1CA2MMP1 | |
| SCHEMBL1108523 | 0.90 | CA1 (0.44) | MMP9MMP2CA1CA2MMP1 | |
| SCHEMBL3458504 | 0.87 | CACNA1H (0.43) | CACNA1HCACNA1BMMP9MMP2CA1 | |
| SCHEMBL1099498 | 0.86 | MMP1 (0.50) | MMP9MMP2MMP1CXCR4MMP13 | |
| SCHEMBL1108515 | 0.86 | MMP1 (0.50) | MMP9MMP2MMP1CXCR4MMP13 | |
| SCHEMBL1100869 | 0.86 | MMP1 (0.50) | MMP9MMP2MMP1CXCR4MMP3 | |
| SCHEMBL1108518 | 0.86 | MMP1 (0.50) | MMP9MMP2MMP1CXCR4MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| EP-1370537-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | CACNA1H 3202/4885CACNA1B 1985/4885MMP9 1/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | CACNA1H 3202/4885CACNA1B 1985/4885MMP9 1/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | CACNA1H 3257/4885CACNA1B 1630/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.